629626-40-0

Basic information

• Product Name: Carbamic acid, [2-(2-iodoethoxy)ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 629626-40-0
• Molecular Formula: C9H18INO3
• Molecular Weight: 315.151
• Mol File: 629626-40-0.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [2-(2-iodoethoxy)ethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-(2-iodoethoxy)ethyl]-, 1,1-dimethylethyl ester(629626-40-0)
• EPA Substance Registry System: Carbamic acid, [2-(2-iodoethoxy)ethyl]-, 1,1-dimethylethyl ester(629626-40-0)

Safety Data

• Hazardous Substances Data: 629626-40-0(Hazardous Substances Data)

Upstream product

• 139115-91-6 2-(2-tert-butyloxycarbonylaminoethoxy)ethanol 
• 603-35-0 triphenylphosphine 
• 192132-77-7 2-(2-(tert-butoxycarbonylamino)ethoxy)ethyl 4-methylbenzenesulfonate 
• 34619-03-9 tert-butyldicarbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 111-46-6 diethylene glycol 

Downstream Products

• 629626-41-1 ethyl (Z)-2-(2-triphenylmethylaminothiazol-4-yl)-2-[2-(2-N-BOC-aminoethoxy)ethoxyimino]acetate 

Relevant articles and documents

ISOINDOLINE DERIVATIVES WHICH BIND TO AN ATP BINDING SITE

The present invention relates to novel probe compounds of formulae I and II defined herein. The present invention also relates to methods of synthesising these novel probe compounds and to their use in assays and screens for determining the binding of a test molecule to the ATP-binding site of a target protein, such as, for example, the Mismatch Repair (MMR) component proteins PMS2 and MLH1, or for determining the location and/or quantity of such target proteins in a biological sample.

Agent for Preventing or Ameliorating Hearing Impairment

It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.

SUBSTITUTED 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE MOLECULES AS PCSK9 ALLOSTERIC BINDERS

The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X1, X2, Y, R1, R2, RA, RB and n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples.